News Stay up to date with our latest announcements! 06/03/20247 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic Read More 05/22/20237 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding Read More 08/01/20227 Hills Pharma Receives $3MM SBIR Grant from NIAID to Accelerate Novel Vaccine Combination Against Chagas Disease Read More 06/09/20227 Hills Pharma Expands Pioneering Patent Portfolio With New Claims Covering Innovative Combination Therapies Read More 05/18/2022New Study Demonstrates Integrin Activation Can Bring the Heat to Cold Melanoma Tumors Read More 03/08/20227 Hills Pharma’s Clinical-stage Novel Immunostimulant 7HP349 Granted FDA Fast Track Designation for Anti-PD-1-resistant Metastatic Melanoma Read More 11/01/20217 Hills Pharma Announces the Completion of a Landmark Phase I Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines Read More 09/14/2021Texas Heart Institute, University of Texas Medical Branch (UTMB) and 7 Hills Pharma Pioneer Significant Vaccine Research Read More 07/26/20217 Hills Pharma Names Biopharma Industry Veteran Michael S. Perry Chairman of its Board of Managers Read More 03/01/2021IMMUNE ACTIVATORS – Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies Read More 12/08/2020Two Incentives that Could Open the Floodgates to Drug Repositioning for COVID-19 Read More 12/07/20207 Hills Pharma CEO Cites Seniors’ Weakened Immune Systems as Challenge for COVID-19 Vaccines’ Effectiveness Read More 11/09/20207 Hills Pharma Announces First Healthy Volunteers Dosed In Landmark Phase 1 Trial of Immunostimulant to Improve Immuno-Oncology Drugs, COVID-19 and Influenza Vaccines Read More 09/16/20207 Hills Pharma Receives $2M SBIR Grant from NCI to Launch Phase 1 Trials of Lead Immunostimulant to Augment Immuno-Oncology Drugs, COVID-19 and Flu Vaccines Read More 08/04/20207 Hills Pharma Awarded Pioneering Patent Estate Covering Integrin Activators to Improve Effectiveness of Immunotherapies Read More 07/07/20207 Hills Pharma Announces Positive Data With Oral Immunostimulant to Improve Effectiveness of COVID-19 Vaccines Read More 06/15/20207 Hills Pharma Highlights Cell Adhesion as Key to Improving Effectiveness of Covid-19 Vaccines and Immuno-Oncology Drugs At BIO Digital 2020 Online Conference Read More 06/04/20207 Hills Pharma to Deliver Video Presentation At BIO Digital 2020 June 8 – 12 Read More 04/14/20207 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly Read More 07/24/20187 Hills Pharma Appoints Lionel D. Lewis as Chief Medical Officer Read More 06/26/20187 Hills Pharma Announces Scientific Advisory Board Formed With Prominent Immuno-Oncology Experts to Help Advance Novel Integrin Activator Program Read More 06/19/20187 Hills Pharma Launches With $2 Million SBIR Grant in Addition to $4 Million in Seed Capital to Pursue Novel Cancer Therapeutics to Promote a Productive Immune Response and Overcome Drug Resistance Read More 09/03/20247 Hills Pharma Safely Doses First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors Read More
